Clinical trial
The SOURCE Study: Schizophrenia Outcomes-utilization, Relapse, and Clinical Evaluation: a Prospective 2-year Observational Study of Patients With Schizophrenia Who Initiate Treatment With Injectable Risperidone Long-acting Microspheres (RISPERDAL CONSTA)
NCT00246194 is registered in ClinicalTrials.gov with Janssen, LP as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The SOURCE Study: Schizophrenia Outcomes-utilization, Relapse, and Clinical Evaluation: a Prospective 2-year Observational Study of Patients With Schizophrenia Who Initiate Treatment With Injectable Risperidone Long-acting Microspheres (RISPERDAL CONSTA)
- Lead sponsor
- Janssen, LP
- Phase
- Observational
- Overall status
- Completed
- Start date
- September 30, 2004
- Completion date
- November 30, 2007
- Enrollment
- 532 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.